Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in HIV-1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial

• Published in: The Journal of infectious diseases 2005-03, Vol.191 (6), p.830-839
• Main Authors: Molina, Jean-Michel, Journot, Valérie, Morand-Joubert, Laurence, Yéni, Patrick, Rozenbaum, Willy, Rancinan, Corinne, Fournier, Sandra, Morlat, Philippe, Palmer, Pierre, Dupont, Bertrand, Goujard, Cécile, Dellamonica, Pierre, Collin, Fidéline, Poizot-Martin, Isabelle
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Benzoxazines; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Didanosine - administration & dosage; Didanosine - adverse effects; Didanosine - therapeutic use; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections - drug therapy; HIV Infections - virology; HIV Protease Inhibitors - administration & dosage; HIV Protease Inhibitors - therapeutic use; HIV-1 - drug effects; Human immunodeficiency virus 1; Humans; Male; Middle Aged; Oxazines - administration & dosage; Oxazines - adverse effects; Oxazines - therapeutic use; Reverse Transcriptase Inhibitors - administration & dosage; Reverse Transcriptase Inhibitors - adverse effects; Reverse Transcriptase Inhibitors - therapeutic use; RNA, Viral - blood; Treatment Outcome
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1086/428091

BackgroundWe assessed a once-daily combination to simplify therapy in patients infected with human immunodeficiency virus type 1 (HIV-1) MethodsA total of 355 adults with plasma HIV-1 RNA levels